What Do Heart Failure Stages and NYHA Classes Mean?
At a Glance
ACC/AHA stages show how heart failure or structural heart disease has progressed, while NYHA classes show how symptoms limit activity today. Stages do not reverse, but NYHA class can improve or worsen with treatment and flare-ups.
In this answer
5 sections
Your ACC/AHA heart failure stage and your NYHA functional class are two different but complementary ways your care team measures your heart health. They are assigned independently and used together to plan your treatment [1]. The ACC/AHA stage describes the structural damage to your heart and whether the disease itself is progressing [1]. It only moves in one direction—you cannot go backward to a prior stage. Your NYHA class describes how much your symptoms (like shortness of breath or fatigue) limit your daily physical activities right now [2]. Unlike your stage, your NYHA class can improve as treatments take effect or worsen during a flare-up [3]. Together, these labels help your doctor determine what medications you need, whether you might benefit from implanted devices, and what your long-term care plan should look like [1].
When to Seek Immediate Help
If you experience severe or sudden shortness of breath at rest, chest pain or pressure, fainting, new confusion, or blue/gray lips, call emergency services immediately. For urgent but non-emergency changes—such as a rapid weight change, increasing swelling, or needing more pillows to sleep—contact your care team promptly and follow your individualized action plan.
Comparing Stage and Class
| Feature | ACC/AHA Heart Failure Stage | NYHA Functional Class |
|---|---|---|
| What it measures | Structural changes to your heart and disease progression [1]. | How much your symptoms limit your physical activity right now [2]. |
| Can it improve? | No. Once you reach a stage, you stay there even if you feel perfectly fine [1]. | Yes. You can move to a lower class if your symptoms improve with treatment, or a higher class during a flare-up [3]. |
| Example | Stage C: You have structural heart changes and currently have (or previously had) symptoms [1]. | Class II: You feel fine sitting down but get winded walking up a flight of stairs [2]. |
ACC/AHA Stages: The Progression of Heart Disease
The American College of Cardiology (ACC) and American Heart Association (AHA) use stages A through D to track structural heart disease—meaning physical changes to the heart muscle or valves, such as thickening, enlargement, or scarring [4].
- Stage A (At Risk): You do not have heart failure or structural heart damage, but you have risk factors like high blood pressure, diabetes, or obesity [1][5].
- Stage B (Pre-Heart Failure): You have never had heart failure symptoms, but tests show structural changes to your heart, abnormal cardiac function, or elevated blood markers [1][4].
- Stage C: You currently have (or previously had) symptoms of heart failure caused by a structural or functional heart abnormality [1]. Anyone with current or prior heart failure symptoms falls into this category.
- Stage D (Advanced): You have severe, persistent symptoms that interfere with daily life, and you experience recurrent hospitalizations or cannot tolerate standard treatments [6][1].
NYHA Classes: Your Daily Symptoms
The New York Heart Association (NYHA) classification is based on your functional capacity [3]. Keep in mind that this assessment is somewhat subjective. Symptoms like breathlessness and fatigue can also be caused by lung disease, anemia, or simply having a “bad day,” so your care team interprets your class based on the overall picture [2].
- Class I (No Limitation): You can do everyday physical activities without feeling overly tired, breathless, or having chest discomfort [2].
- Class II (Slight Limitation): You are comfortable at rest, but ordinary activities (like walking up a flight of stairs or doing yard work) cause fatigue, palpitations, or shortness of breath [2][7].
- Class III (Marked Limitation): You are comfortable at rest, but even less-than-ordinary activities (like walking a short distance or getting dressed) cause symptoms [2].
- Class IV (Severe Limitation): You are unable to do any physical activity without discomfort, and you may even have symptoms while resting [1].
How Your Care Team Uses Them Together
Your doctors do not use your stage and class in isolation. They combine these labels with test results, most importantly your ejection fraction (EF)—the percentage of blood your heart’s main pumping chamber pushes out with each beat [1].
Focusing on Prevention (Stages A and B)
If you are in the early stages without symptoms, treatment focuses heavily on lifestyle changes and managing risk factors [8]. For Stage B, you may also be prescribed specific evidence-based medications, depending on your test results, to actively treat the underlying structural changes and prevent progression to symptomatic heart failure [1].
Intensifying Medications (Stage C)
Once you reach Stage C, your team will start you on Guideline-Directed Medical Therapy (GDMT)—a set of evidence-based medications tailored to your specific condition [1]. For instance, if your ejection fraction is low (a condition called HFrEF), the standard approach often involves four foundational medication classes: a beta-blocker, a mineralocorticoid receptor antagonist (MRA), an SGLT2 inhibitor, and an ARNI or similar drug [9].
However, your doctors will adjust these medications based on your kidney function, potassium levels, blood pressure, and other individual factors [1]. If your NYHA class improves from III to II, it may indicate that your treatment is working well, but you will still remain in Stage C and should never stop your medications without your doctor’s guidance [10].
Considering Devices
If you are in Stage C and continue to experience symptoms with activity (NYHA Class II or III) despite taking optimized medications, your doctor may evaluate you for implanted devices [11]. Your stage and symptom class alone do not qualify you for a device. Whether you need an implantable cardioverter-defibrillator (ICD, which prevents sudden cardiac death from dangerous rhythms) or cardiac resynchronization therapy (CRT, a specialized pacemaker that coordinates the heart’s pumping) depends on your ejection fraction, the electrical patterns on your ECG, your heart rhythm, and your overall expected benefit [11][12].
Planning for Advanced Therapies (Stage D)
Stage D is an overall clinical assessment, not just an automatic result of having Class III or IV symptoms. If your symptoms remain severe and you experience recurrent hospitalizations or cannot tolerate standard medications, your care team will evaluate whether your disease has progressed to Stage D [6][1]. You do not need to exhaust every possible medication and device before asking for a referral to an advanced heart failure specialist [13].
Specialists can evaluate you for advanced options, such as a heart transplant or a mechanical heart pump like a left ventricular assist device (LVAD) [14]. At this stage—and often much earlier—your care plan should also integrate palliative care [15]. Palliative care is specialized medical care focused on relieving symptoms and improving your quality of life; it is a supportive therapy provided alongside active treatment, not the same as giving up or entering hospice [15].
More Than Just a Label
While higher stages and classes are generally linked to a higher risk of complications, these categories are not precise predictions of your individual future [16]. The NYHA class in particular can misalign with your day-to-day reality; you might feel fine sitting in the clinic but struggle to do household chores [2][17]. Always be honest with your care team about what activities you avoid or find difficult, as your personal symptom experience is a critical guide for adjusting your care.
Common questions in this guide
How are ACC/AHA stages different from NYHA classes?
Can my heart failure stage or NYHA class get better?
What does Stage C, Class II heart failure mean?
Does NYHA Class III or IV automatically mean Stage D?
How do ejection fraction and test results affect my treatment?
When should I seek urgent or emergency help for heart failure?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Stage versus class
How does my heart failure stage differ from my NYHA class in planning my care?
Implanted device options
Could my ejection fraction and ECG results affect whether implanted devices are considered for me?
Heart medication planning
How might my kidney function, potassium levels and blood pressure shape my heart medication choices?
Related questions
Show more
Get notified when new evidence is published on congestive heart failure.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (17)
- 1
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Heidenreich PA, Bozkurt B, Aguilar D, et al.
Journal of the American College of Cardiology 2022; (79(17)):1757-1780 doi:10.1016/j.jacc.2021.12.011.
PMID: 35379504 - 2
Integrating the 6-Minute Walk Test Into New York Heart Association Functional Classification.
Chronis L, Duli E, Hill B, et al.
The American journal of cardiology 2025; (255()):110-115 doi:10.1016/j.amjcard.2025.08.006.
PMID: 40803599 - 3
Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry.
Lindberg F, Lund LH, Benson L, et al.
European journal of heart failure 2022; (24(11)):2093-2104 doi:10.1002/ejhf.2644.
PMID: 35999668 - 4
Universal Definition and Classification of Heart Failure.
Bozkurt B, Coats A, Tsutsui H
Journal of cardiac failure 2021; doi:10.1016/j.cardfail.2021.01.022.
PMID: 33662581 - 5
The AHA/ACC/HFSA 2022 Heart Failure Guidelines: Changing the Focus to Heart Failure Prevention.
Abovich A, Matasic DS, Cardoso R, et al.
American journal of preventive cardiology 2023; (15()):100527 doi:10.1016/j.ajpc.2023.100527.
PMID: 37637197 - 6
Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee.
Fang JC, Ewald GA, Allen LA, et al.
Journal of cardiac failure 2015; (21(6)):519-34.
PMID: 25953697 - 7
Patients report more severe daily limitations than recognized by their physicians.
Castro RRT, Joyce E, Lakdawala NK, et al.
Clinical cardiology 2019; (42(12)):1181-1188 doi:10.1002/clc.23269.
PMID: 31571248 - 8
A high-value, cross-continuum approach to heart failure: A narrative review.
Potharazu AV, Mansour AI, Berkowitz S, et al.
The American journal of medicine 2026; doi:10.1016/j.amjmed.2026.07.003.
PMID: 42508626 - 9
The role and application of current pharmacological management in patients with advanced heart failure.
Palazzuoli A, Ruocco G, Del Buono MG, et al.
Heart failure reviews 2024; (29(2)):535-548 doi:10.1007/s10741-024-10383-0.
PMID: 38285236 - 10
Misconceptions and Facts about Heart Failure with Reduced Ejection Fraction.
Krittanawong C, Rodriguez M, Lui M, et al.
The American journal of medicine 2023; (136(5)):422-431 doi:10.1016/j.amjmed.2023.01.024.
PMID: 36740210 - 11
An updated review of cardiac devices in heart failure.
Murphy C, Zafar H, Sharif F
Irish journal of medical science 2017; (186(4)):909-919 doi:10.1007/s11845-017-1597-9.
PMID: 28343276 - 12
Left Ventricular Assist Devices: A Rapidly Evolving Alternative to Transplant.
Mancini D, Colombo PC
Journal of the American College of Cardiology 2015; (65(23)):2542-55.
PMID: 26065994 - 13
Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology.
Crespo-Leiro MG, Metra M, Lund LH, et al.
European journal of heart failure 2018; (20(11)):1505-1535 doi:10.1002/ejhf.1236.
PMID: 29806100 - 14
Advanced Heart Failure: Definition, Epidemiology, and Clinical Course.
Crespo-Leiro MG, Barge-Caballero E
Heart failure clinics 2021; (17(4)):533-545 doi:10.1016/j.hfc.2021.06.002.
PMID: 34511203 - 15
Palliative care in heart failure guidelines: A comparison of the 2021 ESC and the 2022 AHA/ACC/HFSA guidelines on heart failure.
Blum M, Goldstein NE, Jaarsma T, et al.
European journal of heart failure 2023; (25(10)):1849-1855 doi:10.1002/ejhf.2981.
PMID: 37492904 - 16
Prognostic value of quality of life and functional status in patients with heart failure: a systematic review and meta-analysis.
Ali A, Siddiqui AA, Shahid I, et al.
The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology 2024; (76(1)):97 doi:10.1186/s43044-024-00532-z.
PMID: 39101961 - 17
Impact of Patient-Reported Outcome Measurement in Heart Failure Clinic on Clinician Health Status Assessment and Patient Experience: A Substudy of the PRO-HF Trial.
Sandhu AT, Zheng J, Kalwani NM, et al.
Circulation. Heart failure 2023; (16(2)):e010280 doi:10.1161/CIRCHEARTFAILURE.122.010280.
PMID: 36334312
This page is for informational purposes only and does not constitute medical advice. Your heart failure care team should interpret your ACC/AHA stage, NYHA class, test results, and treatment plan.